Rx for Biotech

Our guest for this podcast episode is Laura Hobbs, Director of Healthcare Policy at the American Action Forum. In this episode, we discuss the Inflation Reduction Act impact on Pharma and Patient Access, along with 340b drug pricing and new PBM utilization controls. Learn more about the American Action Forum, and subscribe to their weekly newsletter here: https://www.americanactionforum.org/

In this special episode, listen to Emily Walsh Martin, PhD, Principal at Tremont Therapeutics Consulting, as she shares some of the key highlights from the American Society of Gene and Cell Therapy’s Policy Summit that was held in Washington, DC, on September 18th and 19th, 2023. Check out the full program and register to view the on-demand content online at asgct.org/advocacy/policy-summit/agenda

The Inflation Reduction Act was signed into law in August 2022. In this podcast episode, we look into what lies ahead as the policy implementation begins. Our guest in this episode is Dr. Robert Popovian, a clinical pharmacist and health economist with deep expertise in health policy, drug pricing and affordability, access, and patient advocacy.

Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.

Listen to Francesca Cook, VP of Market Access at Regenexbio, as she provides an overview of the program and what to expect at the American Society of Gene and Cell Therapy’s upcoming Policy Summit being held in Washington, DC, on September 18th and 19th, 2023. Check out the full program and register online at https://asgct.org/advocacy/policy-summit/agenda

In this podcast episode, our guest is Mark McDonough, CEO of ChromaCode. ChromaCode is an innovator in genomics with a multiplexing platform that is driving integration from laboratories to physicians to patients, connecting them to the right treatment through its proven HDPCR™ multiplexing platform. This adaptable technology expands the accessibility of diagnostic applications to patient communit...

In this podcast episode, our guest is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins leveraging their Superkine Platform to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers.

In this podcast episode, Tomasz George, Chief Scientific Officer at Virax Biolabs, shares how the company's ViraxImmune™ technology platform will empower patients to take control of their health and make informed decisions on how to respond to current and future viral threats. The company hopes their ViraxImmune™ platform will shift the way individuals are able to manage aspects of their immune he...

In this podcast episode, Dr. Michael Alonso, VP of Immunology and Pharmacology at Bolt Biotherapeutics, discusses how the company is developing cancer therapies that engage the innate immune system to generate robust anti-tumor responses.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs. In this podcast episode, we speak with Gregory Flesher, President and CEO of Reneo to learn more about mavodelpar, the company's lead asset, which is being developed in two rare diseas...

In this podcast episode, Cyclacel CEO and President, Spiro Rombotis, shares how the company, is exploiting deeper understanding of molecular oncology to develop novel precision medicines based on cell cycle, transcriptional regulation, and mitosis biology.

Chris Leidli reviews scientific and clinical highlights from the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting with guest, Benjamin McLeod, MBIOT.

In this podcast episode, Dr. Philip Kantoff, the CEO, CMO, and Co-Founder of Convergent Therapeutics reviews the company's efforts to develop next-generation radiopharmaceuticals for the treatment of cancer.

FibroBiologics is the leading biotech company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. In this podcast episode, the Founder and CEO, Pete O'Heeron discusses the promise of fibroblast cell therapy to treat diseases such as multiple sclerosis, degenerative disk disease and more.

In this podcast episode, Dr. Erandi De Silva discusses the hybrid approach to gene therapy development at Forge Biologics, Inc., an emerging leader in the contract development and manufacturing (CDMO) market for advanced regenerative medicine products. Dr. De Silva also discusses the unique approach to building a culture and diverse talent pool within the Columbus, Ohio biotech ecosystem.

Forge Biologics is on a mission to enable access to life-changing gene therapies and help bring them from idea into reality. In this podcast episode, we learn about trends in the gene therapy landscape and contract manufacturing from Co-Founder and CEO, Timothy Miller, PhD.

This podcast episode previews the key precision medicine and cellular therapy data being showcased at this year's American Association of Cancer Research annual meeting.

Allen Davidoff, PhD is the Founder and CEO of XORTX Therapeutics, Inc., a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. This podcast episodes looks at novel therapies in development that may extend kidney health.

This podcast episode provides a short recap of the day long workshop hosted by the FDA’s Office of Therapeutic Products (OTP) a new office within CBER. The goal of the workshop was to share knowledge and best practices from experts in the field of advanced manufacturing and analytical technologies (AMAT) for regenerative medicine therapies. Innovative manufacturing technologies and alternative tes...

As Life Science companies grow, they become less efficient. In this podcast episode, Dr. Donald Davis explains what scaling challenges are and what companies can do to become more efficient using the process improvement tools of lean six sigma.

Anyone who has experimented with ChatGPT can get a sense of the potential of generative AI. AI powers driverless cars, spots signs of disease on medical images, finds an answer when you ask Alexa a question, and lets you unlock your phone with your face to talk to friends on the iPhone. Those are just a few ways AI already touches our lives, but there are many ways AI is being utilized in the phar...

In this podcast episode, we recap highlights from JPM Healthcare conference with Chris Dokomajilar from DealForma, Inc., and review 2023 outlook for Biopharma Dealmaking, Financing, and Partnerships. To join live webinar on February 8th, 2023, use this link: https://us02web.zoom.us/j/6097872444

In this podcast episode, Chris provides a short preview of biotechnology and pharmaceutical companies to watch in 2023.

This podcast episode covers the highlights from this year’s American Society of Hematology Annual Meeting that took place in New Orleans in early December. There was enormous excitement for novel therapies for blood cancers and for diseases that previously had very high morbidity and mortality and now, because of novel treatment modalities in the field of hematology, like T cell engagers and CAR-T...

OncoOne is a biotech company developing novel therapeutics for patients with solid tumors and autoimmune diseases. In this podcast episode, Brent Meadows, Chief Business Officer and US General Manager, discusses the role of oxMIF in innate and adaptive immunity and outlines the company's development approach and plan for entering the clinic.